Unite de Fabrication de Medicaments
BBVMT:UMED8.30
TND
0.00
(0.00%)
Unite de Fabrication de Medicaments
BVMT:UMED
(Tunis Stock Exchange)
Recent
price
8.30
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Semi-annual Revenue
FRC
•
in mil. unless spec.Semi-annual Earnings Per Share
FRC
•
in mil. unless spec.Semi-annual Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Unité de Fabrication de Médicaments (UNIMED) is a Tunisia-based pharmaceutical company that develops, manufactures, and commercializes sterile pharmaceutical generics and provides contract manufacturing services for international and regional healthcare companies. Founded in 1989 and headquartered in Kalâa Kebira, Sousse, Tunisia, the company specializes in aseptic processing and sterile formulation across multiple therapeutic classes. UNIMED operates through two primary business divisions, proprietary generic pharmaceuticals and third-party contract manufacturing (CDMO), offering products that include ophthalmic solutions such as anti-inflammatory, antimicrobial, and lubricating eye drops; injectable fluids supplied in sterile ampoules, vials, and infusion bottles; otolaryngology and respiratory treatments comprising nasal sprays, otic drops, and inhalation aerosols; and sterile antibiotic powders including penicillin and cephalosporin formulations. In addition to its domestic market supply across Tunisian public hospitals and private pharmacy networks, UNIMED distributes and exports pharmaceutical products across Europe, North Africa, Sub-Saharan Africa, and the Middle East. In recent operational and strategic developments, UNIMED established a strategic partnership and joint venture with GCUBE to manufacture and market rapid diagnostic test kits for global distribution, advanced its international registration pipeline with more than 100 marketing authorizations (AMMs) across African and Middle Eastern target markets, commissioned a dedicated photovoltaic solar facility supplying approximately 40 percent of its manufacturing plant energy needs, and updated its corporate executive leadership with senior management appointments to accelerate commercial and geographic expansion.